Cynata Therapeutics Limited

As of June 30, 2025, Cynata Therapeutics Limited carries a market capitalization of 31.25M, placing it among publicly traded companies globally. Its enterprise value stands at 26.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cynata Therapeutics Limited's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2025, Cynata Therapeutics Limited has 225.95M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Cynata Therapeutics Limited maintains a current ratio of 4.40, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Cynata Therapeutics Limited posted a negative return on equity (ROE) of -142.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -120.50, reflecting losses generated across the asset base.

As of the close on October 21, 2026, Cynata Therapeutics Limited's stock has declined approximately 95.81% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.18.

These figures cover the twelve months ended June 30, 2025. EBITDA reached -11.21M, while operating income came in at -11.50M.

These figures are as of June 30, 2025. Total book value stands at 5.98M, with working capital of 4.13M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -24.37, meaning Cynata Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cynata Therapeutics Limited's most recent stock split took place on October 12, 2026 with a 71:77 split ratio.